factor V Leiden

02/01/1997 - "Thus the activated protein C resistance assay is not cost-effective in ruling out factor V Leiden in this population."
09/01/2013 - "An improved algorithm for activated protein C resistance and factor V Leiden screening."
05/01/2015 - "Our study emphasizes the presence of other contributory factors towards APC resistance rather than FV Leiden alone. "
01/01/2007 - "In both studies the Pefakit assay showed 100% sensitivity and 100% specificity for detection of the factor V Leiden mutation, compared to 93.1% sensitivity and 93.0% specificity for the COATEST APC Resistance V in the IMCLD study and 93.9% sensitivity and 95.6% specificity in the DUMC study. "
09/01/2005 - "Coagulation studies performed in the neonatal period and at the age of 18 months revealed activated protein C resistance due to factor V Leiden mutation (R506Q). "

12/02/2016 - "Potential effects of inherited thrombophilia, most notably factor V Leiden, on improved embryo implantation in women and sperm counts in men are intriguing, but are currently poorly understood."
01/01/2005 - "Who, what, and when to test continue to be controversial and challenging questions (2); however, laboratories developing new or improved mutation detection methodologies have used the most commonly screened inherited thrombophilia polymorphism, factor V Leiden (R506Q), for many years (3). "
07/01/2020 - "The results of this study support the ischaemic aetiology and establish HTO as an early and reversable stage of hip AN. Factor V Leiden causes a state of hypercoagulability and hypofibrinolysis that encourages the development of THO due to ischaemic causes. "
10/01/2019 - "Thrombophilia study was positive to heterozygous factor V Leiden. "
01/01/2017 - "Gene mutations of factor V-1691 (factor V Leiden) and prothrombin-20210 being considered as the most common thrombophilia markers were analyzed in this study. "

01/01/2008 - "This report suggests that postoperative anticoagulation may be helpful for the successful maturation of vascular anastomoses in children with underlying acquired or hereditary risk factors for thrombosis including factor V Leiden mutation."
09/01/1999 - "ERT may be protective against atherothrombosis when the Factor V Leiden mutation is absent, whereas the Factor V Leiden mutation may increase risk for atherothrombosis, particularly in the presence of ERT. "
01/01/2023 - "The study also found that a certain genetic variation (factor V Leiden), which makes blood more likely to clot, and blood type (non-O) were linked to a higher risk of thrombosis. "
09/01/2010 - "This study was carried out to evaluate if increased numbers or procoagulant potential of circulating MP contribute to the heterogeneity in occurrence of thrombosis in heterozygotes carrying Factor V Leiden (FVL) mutation. "
01/01/2010 - "Thrombosis risk panel studies showed factor V Leiden homozygote mutation. "

04/01/1997 - "Risks for venous thromboembolism in heterozygous carriers of factor V Leiden mutation increased with age at a rate significantly greater than that in noncarriers. "
01/01/2013 - "The objective of this study was to compare standard vs. lifelong anticoagulation in 20-year-old factor V Leiden heterozygotes with unprovoked venous thromboembolism. "
01/01/2012 - "The role of Factor V Leiden in adult patients with venous thromboembolism: a meta-analysis of published studies from Turkey."
11/01/2010 - "The objective of the study was to determine the prevalence of the factor V Leiden (FVL) mutation and its association with obstetric complications, blood loss during delivery, and venous thromboembolism (VTE). "
02/01/2007 - "Update on factor V Leiden association with venous thromboembolism in the LITE Study."

02/01/2023 - "There is no study that specifically analyzes the safety and efficacy of TXA during TJA in patients with factor V Leiden (FVL) mutation; therefore, the purpose of this study was to evaluate the safety and efficacy of TXA use on the risk of VTE and bleeding in patients carrying FVL mutation. "
01/01/2013 - "Studies assessing bleeding risk with anticoagulation in factor V Leiden heterozygotes and the costs of indefinite anticoagulation are needed to determine if lifelong anticoagulation is the optimal strategy."
01/01/1998 - "Trial endpoints will include recurrent VTE, major bleeding episodes and all-cause mortality in the total patient population and separately in those patients with factor V Leiden. "
11/01/2023 - "To the best of our knowledge, this is the first case of a HFL hemorrhage as the initial manifestation of Factor V Leiden disease. "
11/01/2023 - "To report a case of a Henle fiber layer hemorrhage as the initial manifestation of Factor V Leiden disease. "